| Literature DB >> 14962363 |
R Heiner Schirmer1, Boubacar Coulibaly, August Stich, Michael Scheiwein, Heiko Merkle, Jana Eubel, Katja Becker, Heiko Becher, Olaf Müller, Thomas Zich, Wolfgang Schiek, Bocar Kouyaté.
Abstract
Methylene blue has intrinsic antimalarial activity and it can act as a chloroquine sensitizer. In addition, methylene blue must be considered for preventing methemoglobinemia, a serious complication of malarial anemia. As an antiparasitic agent, methylene blue is pleiotropic: it interferes with hemoglobin and heme metabolism in digestive organelles, and it is a selective inhibitor of Plasmodium falciparum glutathione reductase. The latter effect results in glutathione depletion which sensitizes the parasite for chloroquine action. At the Centre de Recherche en Santé de Nouna in Burkina Faso, we study the combination of chloroquine with methylene blue (BlueCQ) as a possible medication for malaria in endemic regions. A pilot study with glucose-6-phosphate dehydrogenase-sufficient adult patients has been conducted recently.Entities:
Mesh:
Substances:
Year: 2003 PMID: 14962363 DOI: 10.1179/135100003225002899
Source DB: PubMed Journal: Redox Rep ISSN: 1351-0002 Impact factor: 4.412